Trials / Terminated
TerminatedNCT02555085
Single Ascending Doses of BIIB063 in Healthy Volunteers
Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) doses and a single subcutaneous (SC) dose of BIIB063 in healthy volunteers. The secondary objectives of the study are to estimate the PK parameters of single ascending IV doses of BIIB063; to estimate the PK parameters and absolute bioavailability (F) of a single SC dose of BIIB063; and to evaluate the immunogenicity of single ascending doses of BIIB063.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BIIB063 | Single ascending IV dose |
| OTHER | Placebo | Single dose |
Timeline
- Start date
- 2015-09-30
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2015-09-21
- Last updated
- 2017-04-18
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02555085. Inclusion in this directory is not an endorsement.